Literature DB >> 8752187

Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke.

E F Jones1, P Calafiore, J J McNeil, A M Tonkin, G A Donnan.   

Abstract

Nonrheumatic atrial fibrillation (AF) frequently coexists with other risk factors for cerebral ischemia. This study was originally designed to determine which combinations of clinical and echocardiographic abnormalities were most closely associated with the risk of cerebral ischemic events. Patients with cerebral ischemic events (n = 214) and community-based control subjects (n = 201) underwent transesophageal echocardiography and carotid artery imaging. Adjusted odds ratios (ORs) were determined using multiple logistic regression analysis. Independent risk factors for cerebral ischemia included diabetes, carotid stenosis, aortic sclerosis, left ventricular dysfunction, left ventricular hypertrophy, left atrial (LA) spontaneous contrast, and proximal aortic atheroma. Nonrheumatic AF in combination with LA spontaneous contrast and LA enlargement showed a strong association with cerebral ischemic events (OR 33.7 [95% confidence interval 4.53 to 251]). In subjects with sinus rhythm or nonrheumatic AF, LA enlargement was not associated with an increased risk of cerebral ischemic events in the absence of LA spontaneous contrast. However, only 2 patients and 1 control subject had nonrheumatic AF without LA spontaneous contrast or LA enlargement. Therefore, study of a larger number of subjects is required to address the issue of whether nonrheumatic AF itself carries increased risk. The combination of nonrheumatic AF with LA spontaneous contrast is a potent risk factor for cerebral ischemia. Ascertaining the risk factor in nonrheumatic AF requires adequate examination for underlying cardiac, aortic, and carotid vascular disease. Transesophageal echocardiography may contribute to this assessment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752187     DOI: 10.1016/s0002-9149(96)00331-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Transthoracic and transesophageal echocardiography in atrial fibrillation.

Authors:  C Stöllberger
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

2.  Dobutamine magnetic resonance imaging as a predictor of myocardial functional recovery after revascularisation.

Authors:  R J Trent; G D Waiter; G S Hillis; F I McKiddie; T W Redpath; S Walton
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

3.  Serum galectin-3 level as a marker of thrombogenicity in atrial fibrillation.

Authors:  Duygu Kocyigit; Kadri Murat Gurses; Muhammed Ulvi Yalcin; Hande Canpinar; Ugur Canpolat; Banu Evranos; Hikmet Yorgun; Necla Ozer; Dicle Guc; Kudret Aytemir
Journal:  J Clin Lab Anal       Date:  2017-03-13       Impact factor: 2.352

4.  Detection of left atrial thrombus in patients with mitral stenosis and atrial fibrillation: retrospective comparison of two-phase computed tomography, transoesophageal echocardiography and surgical findings.

Authors:  Bo Hwa Choi; Sung Min Ko; Hweung Kon Hwang; Meong Gun Song; Je Kyoun Shin; Woon Seok Kang; Tae-Yop Kim
Journal:  Eur Radiol       Date:  2013-07-03       Impact factor: 5.315

5.  Left atrial appendage function in patients with atrial flutter.

Authors:  H Omran; W Jung; R Rabahieh; D MacCarter; S Illien; B Rang; A Hagendorff; R Schimpf; B Lüderitz
Journal:  Heart       Date:  1997-09       Impact factor: 5.994

6.  Imaging of thrombi and assessment of left atrial appendage function: a prospective study comparing transthoracic and transoesophageal echocardiography.

Authors:  H Omran; W Jung; R Rabahieh; P Wirtz; H Becher; S Illien; R Schimpf; B Lüderitz
Journal:  Heart       Date:  1999-02       Impact factor: 5.994

7.  Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation.

Authors:  Ali A Sovari; Samuel C Dudley
Journal:  Front Physiol       Date:  2012-08-06       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.